NASDAQ:EDIT
Editas Medicine, Inc Stock News
$5.68
-0.0300 (-0.525%)
At Close: May 14, 2024
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
03:40pm, Wednesday, 18'th Jan 2023
CRISPR could revolutionize the way we treat thousands of diseases. Many of these diseases occur when mutations affect genes, or when people have the wrong amount of genetic material, the Cleveland
Editas Medicine, Inc. (EDIT) Presents at 41st Annual J.P. Morgan Healthcare Conference (Transcript)
10:39am, Wednesday, 11'th Jan 2023
Editas Medicine, Inc. (NASDAQ:EDIT ) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 7:30 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Baisong Mei - Chief Medica
Editas (EDIT) Dips on Portfolio Reprioritization, To Cut Jobs
01:32pm, Tuesday, 10'th Jan 2023
Editas (EDIT) enters a restructuring and portfolio reprioritization to focus on hemoglobinopathies and in vivo gene editing. The company is to reduce its workforce by almost 20%.
Why Editas Medicine Stock Is Sliding Today
11:59am, Monday, 09'th Jan 2023
The gene-editing pioneer announced a big shake-up with its research and development programs.
Editas Medicine tumbles more than 7% after announcing job cuts, restructuring
11:54am, Monday, 09'th Jan 2023
Editas Medicine Inc. [s: edit] is cutting approximately 20% of its workforce. The company reported 1,800 employees as of May 31, according to its annual report.
10 Potential 10x Return Stocks For The Next 10 Years
11:04am, Wednesday, 04'th Jan 2023
While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or i
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
06:30am, Wednesday, 04'th Jan 2023
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the Company's President and CEO Gilmore O'Neill,
Editas Medicine, Inc. (EDIT) EDIT-301 Clinical Update 2022 - (Transcript)
12:11pm, Tuesday, 06'th Dec 2022
Editas Medicine, Inc. (NASDAQ:EDIT ) EDIT-301 Clinical Update Call December 6, 2022 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Gilmore O'Neill - President and Chief Executive Of
2 Beaten-Down Stocks to Watch Closely Next Year
09:53am, Tuesday, 06'th Dec 2022
These biotechs could skyrocket in 2023, but only if they can execute their plans.
Editas shares jump 9% on positive news from sickle-cell study
08:00am, Tuesday, 06'th Dec 2022
Shares of Editas Medicine Inc. EDIT, -4.10% rallied 9.3% in premarket trading on Tuesday after the company said in a news release that it had positive results from the first two patients enrolled in a
Why Shares of Editas Medicine Dropped 15.5% in November
04:56pm, Monday, 05'th Dec 2022
The biotech's shares plummeted after it paused a key clinical trial.
Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why
02:17pm, Monday, 28'th Nov 2022
Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase I/II BRILLIANCE study on EDIT-101, treating Leber congenital amaurosis type 10.
Where Will Editas Medicine Be in 1 Year?
08:30am, Sunday, 20'th Nov 2022
The company could continue lagging the market for a while.
Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus
02:18pm, Thursday, 03'rd Nov 2022
Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.
Editas Medicine, Inc. (EDIT) Q3 2022 Earnings Call Transcript
10:50am, Wednesday, 02'nd Nov 2022
Editas Medicine, Inc. (NASDAQ:EDIT ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Gilmore O'Neill - Chief Executive Officer Baiso
